z-logo
open-access-imgOpen Access
Extracorporeal Photopheresis in Graft-versus-Host Disease
Author(s) -
Beatrice Drexler,
Andreas Buser,
Laura Infanti,
Gregor Stehle,
Joerg Halter,
Andreas Holbro
Publication year - 2020
Publication title -
transfusion medicine and hemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 39
eISSN - 1660-3818
pISSN - 1660-3796
DOI - 10.1159/000508169
Subject(s) - extracorporeal photopheresis , medicine , photopheresis , leukapheresis , graft versus host disease , immunosuppression , clinical trial , extracorporeal , refractory (planetary science) , intensive care medicine , disease , immunology , surgery , stem cell , physics , biology , astrobiology , cd34 , genetics
Background and Summary: Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used in the therapy of acute and chronic graft-versus-host disease (aGvHD, cGvHD) and other diseases. Based on the substantial efficacy and the excellent safety profile in the absence of immunosuppression ECP has established itself as a major treatment form for steroid-refractory GvHD. Here we review the current literature on ECP as a treatment option for patients with aGvHD as well as cGvHD. Key Messages: ECP is a well-established second-line therapy for cGvHD. Its role in the treatment of aGvHD is less clear but also points towards an effective second-line therapy option. In the future ECP could play a role in the prevention of GvHD. More experimental and randomized controlled trials are needed to define the best patient selection criteria, settings, and therapy regimens for GvHD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here